Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a type of aggressive blood cancer called CD20+ B-cell non-Hodgkin lymphoma (B-NHL), and whose cancer has continued to grow or come back after at least two different treatment courses that included specific types of cancer-fighting drugs (an anti-CD20 antibody and an alkylating agent).
• People whose cancer can be detected and measured on imaging scans such as a CT scan, as defined by the trial's guidelines.
• People who are in relatively good physical condition, rated 0 or 1 on a standard health scale used by doctors (meaning fully active or able to carry out light activity).
• People whose bone marrow, kidneys, and liver are functioning at an acceptable level as defined by the trial's guidelines.
• People who are able to provide a tumour tissue sample (either a recent or previously collected sample) for testing at a central laboratory before joining the trial.
• People in the later phase of the trial who are willing to have a tumour biopsy during the study, if the trial doctor considers there is a safely accessible tumour site that can be biopsied without significant risk.

Who may not be able to join:

• People who have previously had a stem cell transplant from a donor, a solid organ transplant, or who have been treated with a type of drug called an anti-CD20 x anti-CD3 bispecific antibody (for example, odronextamab).
• People who have been diagnosed with a specific type of lymphoma called Mantle Cell Lymphoma (MCL).
• People whose lymphoma started in or has spread to the brain or spinal cord.
• People who have received any systemic (whole-body) lymphoma treatment within a specific timeframe before the trial starts, as outlined in the trial guidelines.
• People who have had standard radiotherapy within 14 days before the first dose of the trial drug.
• People who have been taking steroid medicines (such as prednisone) at a dose higher than 10 mg per day within 72 hours before starting the trial drug.
• People with certain other significant health conditions, as described in the trial protocol (confirm with trial site).
• People with certain active infections, as described in the trial protocol (confirm with trial site).
• People who are allergic to both allopurinol and rasburicase (two medicines used to manage a potential side effect of cancer treatment).

Important: Always verify eligibility with the trial site directly before applying.